Edition:
United Kingdom

Recro Pharma Inc (REPH.OQ)

REPH.OQ on NASDAQ Stock Exchange Capital Market

8.77USD
16 Jan 2018
Change (% chg)

$-0.10 (-1.13%)
Prev Close
$8.87
Open
$8.94
Day's High
$9.02
Day's Low
$8.72
Volume
15,469
Avg. Vol
24,571
52-wk High
$10.55
52-wk Low
$5.85

Select another date:

Wed, Jan 3 2018

BRIEF-Recro Pharma - ‍Ryan Lake Promoted To CFO

* RECRO PHARMA INC - ‍RYAN D. LAKE HAS BEEN PROMOTED TO CHIEF FINANCIAL OFFICER​ Source text for Eikon: Further company coverage:

BRIEF-Recro Pharma Says Entered Into A Sales Agreement With Cowen And Co‍​

* RECRO PHARMA INC - ENTERED INTO A SALES AGREEMENT WITH COWEN AND COMPANY‍​

BRIEF-Recro Pharma secures $100 million credit facility

* Recro Pharma Inc - ‍has secured a $100 million credit facility from funds managed by Athyrium Capital Management, LP​

BRIEF-Recro Pharma reports Q3 revenue $17.1 million

* Recro Pharma Inc - ‍Raising its guidance for 2017 revenue from a range of $60-$63 million to $65 million​

BRIEF-RECRO PHARMA ANNOUNCES PDUFA DATE OF MAY 26, 2018 FOR IV MELOXICAM 30MG

* RECRO PHARMA - U.S. FDA HAS SET A PDUFA DATE OF MAY 26, 2018 FOR ITS DECISION ON NEW DRUG APPLICATION (NDA) FOR INTRAVENOUS (IV) MELOXICAM 30MG Source text for Eikon: Further company coverage:

BRIEF-Recro Pharma announces FDA acceptance for review of new drug application for IV Meloxicam 30mg

* Recro Pharma announces FDA acceptance for review of new drug application for IV Meloxicam 30mg Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

BRIEF-Recro Pharma quarterly ‍loss per share $0.48

* Qtrly ‍loss per share $0.48; Co is raising its guidance for 2017 revenue from a range of $55-$60 million to $60-$63 million​ Source text for Eikon: Further company coverage:

BRIEF-Recro Pharma submits new drug application for IV Meloxicam 30mg

* Recro Pharma submits new drug application for IV Meloxicam 30mg Source text for Eikon: Further company coverage:

Select another date: